Gene-Guided reflux drug may tame childhood asthma

NCT ID NCT03015610

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether adjusting the dose of a common acid reflux medicine (lansoprazole) based on a child's genes could improve asthma control. 41 children aged 6-17 with uncontrolled asthma and mild reflux participated. Researchers measured changes in asthma symptoms and reflux over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

lansoprazole

What this could lead to

If successful, this could lead to personalized dosing of acid reflux medicine to better control asthma in children.

What could go wrong

This is a small, completed Phase 3 trial with only 41 participants, so results may not apply to all children. The benefit of gene-guided dosing over standard care remains uncertain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Nemours Children's Specialty Care

    Jacksonville, Florida, 32207, United States